Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Эффекты Lactobacillus Plantarum PS128 у детей с РАС

14 сентября 2026 г. обновлено: Chang Gung Memorial Hospital

Влияние Lactobacillus Plantarum PS128 на детей с расстройствами аутистического спектра

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.

Обзор исследования

Тип исследования

Интервенционный

Регистрация (Действительный)

41

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 7 лет до 12 лет (Ребенок)

Принимает здоровых добровольцев

Да

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • (1) Age 7 to 12 years old.
  • (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
  • (3) Normal control group: Children without autism spectrum disorder.

Exclusion Criteria:

  • (1) Receiving antibiotics within one month.
  • (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
  • (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
  • (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
  • (5) Those with a history of cancer.
  • (6) Those who are allergic to lactic acid bacteria.
  • (7) Not eligible judged by PI

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Другой
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: PS128

Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.

Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.

Плацебо Компаратор: Placebo

Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.

The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.

Без вмешательства: Normal control

Normal control group are enrolled by invitation from the age and gender matched healthy children.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Changes of Total Scores of Social Responsiveness Scale
Временное ограничение: Baseline, Week 12 and Week 16

Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.

Baseline, Week 12 and Week 16

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Changes of Total Scores of Repetitive Behavior Scale-Revised
Временное ограничение: Baseline, Week 12 and Week 16

Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Child Behavior Checklist
Временное ограничение: Baseline, Week 12 and Week 16

Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The score ranges from 0-240. The lower scores stand for better behavioral and emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Adaptive Behavior Assessment System
Временное ограничение: Baseline, week 12 and Week 16

Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior.

Baseline, week 12 and Week 16
Changes in Accuracy of Frith-Happe Animation
Временное ограничение: Baseline, Week 12 and Week 16

A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition.

Baseline, Week 12 and Week 16
Changes in Accuracy of Eyes Task
Временное ограничение: Baseline, Week 12 and Week 16

An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills.

Baseline, Week 12 and Week 16
Changes of Total Scores of Aberrant Behavior Checklist
Временное ограничение: Baseline, Week 12 and Week 16

Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The score ranges from 0-174. The lower scores stand for less aberrant behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Emotional Dysregulation Inventory
Временное ограничение: Baseline, Week 12 and Week 16

Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Parenting Stress Index, Fourth Editon
Временное ограничение: Baseline, Week 12 and Week 16

Parenting Stress Index is a parents' report questionnaire for parenting stress. The score ranges from 0-180. The lower scores stand for lower parenting stress.

Baseline, Week 12 and Week 16
Assessment of Clinical Global Impression-Severity of Illness
Временное ограничение: Week 12 and Week 16

The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The score ranges from 1-7. CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.

Week 12 and Week 16
Assessment of Patient Global Impression of Change
Временное ограничение: Week 12 and Week 16

The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. The score ranges from 1-7. Patients rate their change as "1=very much improved ," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse)."

Week 12 and Week 16
Gut Microbiota-Relative Abundance of Bifidobacterium Faecale
Временное ограничение: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota

Baseline and Week 12
MRI T1
Временное ограничение: Baseline and Week 12

Brain structural volumes (cm²). The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal
Временное ограничение: Baseline and Week 12

Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Diffusion Tensor Imaging (DTI) - FA
Временное ограничение: Baseline and Week 12

Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Safety Assessment - Albumin
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as albumin (3.5-5.4 g/dl).

Baseline and Week 12
Safety Assessment - Total Protein
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as total protein (6.4-8.3 g/dl).

Baseline and Week 12
Safety Assessment - ALP
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALP (135-320 U/L).

Baseline and Week 12
Safety Assessment - Total Bilirubin
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as total bilirubin (0.3-1.2 mg/dl).

Baseline and Week 12
Safety Assessment - T-Cholesterol
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL).

Baseline and Week 12
Safety Assessment - Uric Acid
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as uric acid (<7.0 mg/dl).

Baseline and Week 12
Safety Assessment - BUN
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as BUN (7-25 mg/dl).

Baseline and Week 12
Safety Assessment - Creatinine
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as creatinine (0.2-1.0 mg/dl).

Baseline and Week 12
Safety Assessment - AST
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as AST (13-40 U/L).

Baseline and Week 12
Safety Assessment - ALT
Временное ограничение: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALT (7-40 U/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - MPO
Временное ограничение: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-1β
Временное ограничение: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - TGF-β1
Временное ограничение: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - Eotaxin
Временное ограничение: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-6
Временное ограничение: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Serotonin
Временное ограничение: Baseline and Week 12

Oxidative stress is assessed via Serotonin (ng/mL).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - GABA
Временное ограничение: Baseline and Week 12

Oxidative stress is assessed via GABA (μmol/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Cortisol
Временное ограничение: Baseline and Week 12

Oxidative stress is assessed via Cortisol (6-10am 4.82-19.5, 4-8pm 2.47-11.9, μg/dl).

Baseline and Week 12
Gut Microbiota-Relative Abundance of Lactiplantibacillus Plantarum
Временное ограничение: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota.

Baseline and Week 12

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

15 июля 2022 г.

Первичное завершение (Действительный)

3 апреля 2024 г.

Завершение исследования (Действительный)

3 апреля 2024 г.

Даты регистрации исследования

Первый отправленный

14 марта 2022 г.

Впервые представлено, что соответствует критериям контроля качества

24 марта 2022 г.

Первый опубликованный (Действительный)

1 апреля 2022 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

6 октября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

14 сентября 2026 г.

Последняя проверка

1 февраля 2025 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • 202101416A3

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться